| Vitrakvi (larotrectinib) / Bayer |
VICTORIA, NCT05192642: A Study Called to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice |
|
|
| Completed | N/A | 368 | US | Larotrectinib(Vitrakvi, BAY2757556), Data on other treatments | Bayer | Solid Tumors Harboring NTRK Fusion | 08/23 | 08/23 | | |
LAROTRACKING, NCT04814667: A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib |
|
|
| Active, not recruiting | N/A | 27 | Europe | | Centre Leon Berard, Bayer | Solid Tumor, Adult, Locally Advanced Solid Tumor, Metastatic Cancer | 11/24 | 06/25 | | |
NCT04945330: NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes |
|
|
| Recruiting | N/A | 100 | Japan | Larotrectinib (Vitrakvi, BAY2757556) | Bayer | Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion | 06/29 | 12/29 | | |
ON-TRK, NCT04142437: Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body |
|
|
| Recruiting | N/A | 300 | Europe, Canada, Japan, US, RoW | larotrectinib(Vitrakvi, BAY2757556) | Bayer | Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion | 11/29 | 03/30 | | |
